Adult BSA ≥1.5 m2 Standard initial dose: 60 mg (equiv to tegafur) bd for 28 consecutive days followed by a 14-day rest.
1.25-<1.5 m2 Standard initial dose: 50 mg (equiv to tegafur) bd for 28 consecutive days followed by a 14-day rest. <1.25 m2 Standard initial dose: 40 mg (equiv to tegafur) bd for 28 consecutive days followed by a 14-day rest.
Should be taken with food: Take after breakfast & evening meals.
Contraindications
Severe hypersensitivity. Patients w/ severe bone marrow depression. Concomitant use w/ other fluoropyrimidine-group anti-cancer drugs & flucytosine. Severe renal & hepatic impairment. Women of childbearing potential. Pregnancy.
Discontinue w/ occurrence of jaundice. Potential serious blood dyscrasias in combination w/ other fluoropyrimidine-group anti-cancer drugs & flucytosine. Laboratory tests should be conducted frequently. Periodic hepatic function tests to detect hepatic disorder early. Patients w/ bone marrow depression, infectious disease, abnormal glucose tolerance, current or previous history of interstitial pneumonia, current or previous history of heart disease, GI ulcer or hemorrhage. May cause or aggravate interstitial pneumonia w/ a possible fatal outcome. Potential gonadic effects to reproducible patients. Confirm status of previous exposure to hepatitis infection prior to administration. Caution for signs & symptoms of Hepatitis B reactivation; monitor hepatic function tests or viral markers. Lactation. Childn. Elderly.
Sign Out
